AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005 Jul 01; 11(13):4941-7.

View in: PubMed

subject areas

Animals
Antineoplastic Agents
Apoptosis
Benzamides
Blotting, Western
Caspase 3
Caspases
Cell Cycle
Cell Line, Tumor
Cell Survival
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm
Female
Fusion Proteins, bcr-abl
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mice
Mice, SCID
Models, Molecular
Phosphorylation
Piperazines
Pyrimidines
Survival Analysis
Time Factors
Treatment Outcome
Xenograft Model Antitumor Assays

authors with profiles

HAGOP M KANTARJIAN
JORGE E CORTES
SRDAN VERSTOVSEK